In Silico and Experimental Evaluation of Myricetin in Insulin Resistance‐Associated PCOS in Rats
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202502165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Priya Aswal und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, India. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Insulin Resistance, Flavonoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a prevalent endocrinal disease characterized by hyperandrogenism, insulin resistance, cardiometabolic dysfunction, and hormonal disturbances, often leading to infertility. IR, a hallmark feature of PCOS, is observed in 30%–95% of women with PCOS. Current therapies are associated with potential side effects, necessitating exploration of alternative strategies. The present study aimed to identify and evaluate natural phytoconstituents targeting insulin receptor substrate‐1 (IRS‐1), a critical mediator in insulin signaling. In silico molecular docking of 22 phytoconstituents against IRS‐1 revealed myricetin (MYR) has a binding energy of −9.3 kcal/mol, and favorable ADMET characteristics. MYR also showed significant binding affinity against PI3K and NF‐κB (−8.6 and −7.0 kcal/mol, respectively), indicating its potential to improve insulin sensitivity. Subsequently, the therapeutic efficacy of MYR was assessed in a high‐fat diet and letrozole induced PCOS in rats. MYR treatment at varying doses significantly ( p < 0.001) reversed PCOS associated with metabolic and reproductive abnormalities. MYR (300 mg/kg) demonstrated substantial improvements in body weight, BMI, estrous cycle, restored hormonal balance, and improved IR. MYR significantly improved β‐cell functions, serum lipid profile, oxidative stress, and histology in ovarian tissues. The findings of the study underscore the potential of MYR as safe and effective candidate for PCOS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, India.
- Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
- College of Pharmacy, COER University, Roorkee, India.
ORCID-Profile: Mamta F Singh
Zitieren
APA
Aswal, P., Jangwan, N. S., Dobhal, S., Bisht, S., & Singh, M. F. (2025). In Silico and Experimental Evaluation of Myricetin in Insulin Resistance‐Associated PCOS in Rats. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502165
Vancouver
Aswal P, Jangwan NS, Dobhal S, Bisht S, Singh MF. In Silico and Experimental Evaluation of Myricetin in Insulin Resistance‐Associated PCOS in Rats. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202502165
BibTeX
@article{Aswal2025,
author = {Aswal, Priya and Jangwan, Nitish Singh and Dobhal, Swati and Bisht, Shradha and Singh, Mamta F},
title = {In Silico and Experimental Evaluation of Myricetin in Insulin Resistance‐Associated PCOS in Rats},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202502165}
}
EUVIMED